Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24609214 | 0.82 | IDO1 (0.33) | IDO1TDO2 | |
| SCHEMBL18949168 | 0.77 | — | — | |
| SCHEMBL15935274 | 0.72 | TNKS (0.31) | TNKSTNKS2DGAT1 | |
| SCHEMBL12929926 | 0.72 | NAMPT (0.33) | TNKSDGAT1 | |
| SCHEMBL27193413 | 0.69 | MAPT (0.32) | — | |
| SCHEMBL15461424 | 0.69 | TNKS (0.43) | TNKSTNKS2IDO1TDO2DGAT1 | |
| SCHEMBL21646361 | 0.69 | EGFR (0.33) | IDO1 | |
| SCHEMBL19131465 | 0.69 | — | — | |
| SCHEMBL29297345 | 0.68 | — | — | |
| SCHEMBL19682273 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Northern Industrial Area, (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | TNKS 1630/4885TNKS2 1010/4885IDO1 1533/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | TNKS 3704/4885TNKS2 3624/4885IDO1 2650/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | TNKS 3704/4885TNKS2 3624/4885IDO1 2650/4885 |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | TNKS 699/4885TNKS2 527/4885IDO1 2765/4885 |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | PRKACA, PRKDC, PRKACB | TNKS 699/4885TNKS2 527/4885IDO1 2765/4885 |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | TNKS 372/4885TNKS2 369/4885IDO1 4755/4885 |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | ERBB2, EGFR, ERBB3 | TNKS 1651/4885TNKS2 1001/4885IDO1 1570/4885 |
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | TNKS 1275/4885TNKS2 704/4885IDO1 700/4885 |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | TNKS 372/4885TNKS2 369/4885IDO1 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.